Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 14/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17654175 | 1.00 | GLS (0.57) | GLSALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL17654178 | 1.00 | GLS (0.57) | GLSALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL17654094 | 0.91 | ALDH1A1 (0.61) | GLSALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL17654083 | 0.87 | GLS (0.54) | GLSALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL17654149 | 0.80 | GLS (0.50) | GLSALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL17654088 | 0.80 | GLS (0.50) | GLSALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL17654141 | 0.77 | ALDH1A1 (0.55) | GLSALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL18006623 | 0.76 | ALDH1A1 (0.68) | GLSALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL2945529 | 0.76 | SCD (0.58) | GLSALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL2945534 | 0.76 | SCD (0.58) | GLSALDH1A1HPGDMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | disclosed |
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-06 | — | — | US | disclosed |
| US-10245254-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-04-02 | — | — | US | disclosed |
| US-10245254-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| WO-2016054388-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054388-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | GLS 3/4885ALDH1A1 959/4885HPGD 1767/4885 |
| US-10245254-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | GLS 3/4885ALDH1A1 959/4885HPGD 1767/4885 |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | GLS 3/4885ALDH1A1 968/4885HPGD 1751/4885 |
| US-11013724-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | GLS 3/4885ALDH1A1 968/4885HPGD 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.